Association between cell-bound blood amyloid-β(1-40) levels and hippocampus volume

Alzheimer's Research and Therapy

Volumn 6, Issue 1, 2014, Pages

  Sotolongo Grau, Oscar ^a   Pesini, Pedro ^b   Valero, Sergi ^a,c   Lafuente, Asunción ^a   Buendía, Mar ^a   Pérez Grijalba, Virginia ^b   José, Itziar San ^b   Ibarria, Marta ^a   Tejero, Miguel A ^d   Giménez, Joan ^d   Hernández, Isabel ^a   Tárraga, Lluís ^a   Ruiz, Agustín ^a   Boada, Mercé ^a   Sarasa, Manuel ^b  

^a Institut Catala de Neurociencies Aplicades   (Spain)

^b Araclon Biotech   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d Institut Clinica Corachan   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; APOLIPOPROTEIN E; CREATININE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; EDUCATIONAL STATUS; ENTORHINAL CORTEX; FEMALE; HIPPOCAMPUS; HUMAN; LEFT HEMISPHERE; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 84989208799     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-014-0056-3     Document Type: Article

References (29)

1. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative: The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement 2012, 8:S1-S68.
2. Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR Jr, Weiner MW, Alzheimer's Disease Neuroimaging Initiative: MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 2009, 132:1067-1077.
3. Fletcher LC, Burke KE, Caine PL, Rinne NL, Braniff CA, Davis HR, Miles KA, Packer C: Diagnosing Alzheimer's disease: Are we any nearer to useful biomarker-based, non-invasive tests? GMS Health Technol Assess 2013, 9:Doc01.
4. Pesini P, P?rez-Grijalba V, Monle?n I, Boada M, T?rraga L, Mart?nez-Lage P, San-Jos? I, Sarasa M: Reliable measurements of the β-Amyloid pool in blood could help in the early diagnosis of AD. Int J Alzheimers Dis 2012, 2012:604141.
5. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD: Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003, 61:1185-1190.
6. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM: Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 2000, 57:100-105.
7. Seppal? TT, Herukka SK, H?nninen MT, Tervo S, Hallikainen M, Soininen H, Pirttil? TT: Plasma Aβ42 and Aβ40 as markers of cognitive change in follow-up: A prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry 2010, 81:1123-1127.
8. van Dijk EJ, Prins ND, Vermeer SE, Hofman A, van Duijn CM, Koudstaal PJ, Breteler MM: Plasma amyloid β, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 2004, 55:570-575. 9. Chiu MJ, Yang SY, Chen TF, Chieh JJ, Huang TZ, Yip PK, Yang HC, Cheng TW, Chen YF, Hua MS, Horng HE: New assay for old markers-plasma β amyloid of mild cognitive impairment and Alzheimer's disease. Curr Alzheimer Res 2012, 9:1142-1148.
9. Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Roberts BR, Perez KA, Li QX, Laws SM, Taddei K, Rainey-Smith S, Robertson JS, Vandijck M, Vanderstichele H, Barnham KJ, Ellis KA, Szoeke C, Macaulay L, Rowe CC, Villemagne VL, Ames D, Martins RN, Bush AI, Masters CL, AIBL research group: Changes in plasma amyloid β in a longitudinal study of aging and Alzheimer's disease. Alzheimers Dement 2014, 10:53-61.
10. Toledo JB, Shaw LM, Trojanowski JQ: Plasma amyloid β measurements-A desired but elusive Alzheimer's disease biomarker. Alzheimers Res Ther 2013, 5:8.
11. Ravi LB, Poosala S, Ahn D, Chrest FJ, Spangler EL, Jayakumar R, Nagababu E, Mohanty JG, Talan M, Ingram DK, Rifkind JM: Red cell interactions with amyloid-β(1-40) fibrils in a murine model. Neurobiol Dis 2005, 19:28-37.
12. P?rez-Grijalba V, Pesini P, Monle?n I, Boada M, T?rraga L, Ruiz-Laza A, Mart?nez-Lage P, San-Jos? I, Sarasa M: Several direct and calculated biomarkers from the amyloid-β pool in blood are associated with an increased likelihood of suffering from mild cognitive impairment. J Alzheimers Dis 2013, 36:211-219.
13. Alegret M, Espinosa A, Vinyes-Junqué G, Valero S, Hernández I, Tárraga L, Becker JT, Boada M: Normative data of a brief neuropsychological battery for Spanish individuals older than 49. J Clin Exp Neuropsychol 2012, 34:209-219.
14. Petersen R, Smith G, Waring S, Ivnik R, Tangalos E, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56:303-308.
15. Petersen R, Morris J: Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 2005, 62:1106-1163.
16. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P: Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6:734-746.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
18. Blesa R, Pujol M, Aguilar M, Santacruz P, Bertran-Serra I, Hernández G, Sol JM, Peña-Casanova J: Clinical validity of the 'mini-mental state' for Spanish speaking communities. Neuropsychologia 2001, 39:1150-1157.
19. Han X, Jovicich J, Salat D, van der Kouwe A, Quinn B, Czanner S, Busa E, Pacheco J, Albert M, Killiany R, Maguire P, Rosas D, Makris N, Dale A, Dickerson B, Fischl B: Reliability of MRI-derived measurements of human cerebral cortical thickness: The effects of field strength, scanner upgrade and manufacturer. Neuroimage 2006, 32:180-194.
20. Reuter M, Schmansky NJ, Rosas HD, Fischl B: Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 2012, 61:1402-1418.
21. Rosas H, Liu A, Hersch S, Glessner M, Ferrante R, Salat D, van der Kouwe A, Jenkins B, Dale A, Fischl B: Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002, 58:695-701.
22. Kuperberg G, Broome M, McGuire P, David A, Eddy M, Ozawa F, Goff D, West W, Williams S, van der Kouwe A, Salat DH, Dale AM, Fischl B: Regionally localized thinning of the cerebral cortex in schizophrenia. Arch Gen Psychiatry 2003, 60:878-888.
23. Salat D, Buckner RL, Snyder AZ, Greve DN, Desikan RS, Busa E, Morris JC, Dale A, Fischl B: Thinning of the cerebral cortex in aging. Cereb Cortex 2004, 14:721-730.
24. Figurski MJ, Waligorska T, Toledo J, Vanderstichele H, Korecka M, Lee VM, Trojanowski JQ, Shaw LM: Improved protocol for measurement of plasma β-Amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. Alzheimers Dement 2012, 8:250-260.
25. Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW, Jack CR Jr, Jagust W, Decarli C, Toga AW, Toledo E, Xie SX, Lee VM, Trojanowski JQ, Shaw LM: Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol 2011, 122:401-413.
26. R Core Team: R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2012.
27. Arvanitakis Z, Lucas JA, Younkin LH, Younkin SG, Graff-Radford NR: Serum creatinine levels correlate with plasma amyloid β protein. Alzheimer Dis Assoc Disord 2002, 16:187-190.
28. Metti AL, Cauley JA, Ayonayon HN, Harris TB, Rosano C, Williamson JD, Yaffe K: The demographic and medical correlates of plasma Aβ40 and Aβ42. Alzheimer Dis Assoc Disord 2013, 27:244-249.
29. Ruiz A, Pesini P, Espinosa A, Pérez-Grijalba V, Valero S, Sotolongo-Grau O, Alegret M, Monleón I, Lafuente A, Buendía M, Ibarria M, Ruiz S, Hernández I, San José I, Tárraga L, Boada M, Sarasa M: Blood amyloid β levels in healthy, mild cognitive impairment and Alzheimer's disease individuals: replication of diastolic blood pressure correlations and analysis of critical covariates. PLoS One 2013, 8:e81334.